Role of TNF-α receptors in mice intoxicated with the parkinsonian toxin MPTP

Experimental Neurology

Volumn 177, Issue 1, 2002, Pages 183-192

  Rousselet, Estelle ^a   Callebert, Jacques ^b   Parain, Karine ^a   Joubert, Chantal ^a   Hunot, Stéphane ^a   Hartmann, Andreas ^a   Jacque, Claude ^a   Perez Diaz, Fernando ^a   Cohen Salmon, Charles ^a   Launay, Jean Marie ^b   Hirsch, Etienne C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Behavior; Inflammation; MPTP; Neuroprotection; Parkinson's disease; TNF

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; TUMOR NECROSIS FACTOR ALPHA 1; TUMOR NECROSIS FACTOR ALPHA 2; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; AUTOPSY; BRAIN LEVEL; CELL POPULATION; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; KNOCKOUT MOUSE; MALE; MOTOR ACTIVITY; MOUSE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 0036432917     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2002.7960     Document Type: Article

References (82)

1. Akaneya, Y., M. Takahashi, and H. Hatanaka. 1995. Selective acid vulnerability of dopaminergic neurons and its recovery by brain-derived neurotrophic factor. Brain Res. 704: 175-183.
2. Aloe, L., and M. Fiore. 1997. TNF-alpha expressed in the brain of transgenic mice lowers central tyroxine hydroxylase immunoreactivity and alters grooming behavior. Neurosci. Lett. 238: 65-68.
3. Appel, E., O. Kolman, G. Kazimirsky, P. M. Blumberg, and C. Brodie. 1997. Regulation of GDNF expression in cultured astrocytes by inflammatory stimuli. Neuroreport 8: 3309-3312.
4. Barger, S. W., D. Horster, K. Furukawa, Y. Goodman, J. Kriegl-stein, and M. P. Mattson. 1995. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: Evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc. Natl. Acad. Sci. USA 92: 9328-9332.
5. Baud, V., and M. Karin. 2001. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11: 372-377.
6. Beutler, B., and A. Cerami. 1988. Tumor necrosis, cachexia, shock, and inflammation: A common mediator. Annu. Rev. Biochem. 57: 505-518.
7. Boka, G., P. Anglade, D. Wallach, F. Javoy-Agid, Y. Agid, and E. C. Hirsch. 1994. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 172: 151-154.
8. Bolin, L. M., I. S. Trycharska-Orczyk, J. Santos, M. Lavasani, A. McCormack, J. W. Langston, and D. Di Monte. 2001. Increased vulnerability of dopaminergic neurons in MPTP-lesioned IL-6 KO mice. Soc. Neurosci. Abstr. 194.8.
9. Brenner, D. A., M. O'Hara, P. Angel, M. Chojkier, and M. Karin. 1989. Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. Nature 337: 661-663.
10. Bruce-Keller, A. J., J. W. Geddes, P. E. Knapp, R. W. McFall, J. N. Keller, F. W. Holtsberg, S. Parthasarathy, S. M. Steiner, and M. P. Mattson. 1999. Anti-death properties of TNF against metabolic poisoning: Mitochondrial stabilization by MnSOD. J. Neuroimmunol. 93: 53-71.
11. Bruce, A. J., W. Boling, M. S. Kindy, J. Peschon, P. J. Kraemer, M. K. Carpenter, F. W. Holtsberg, and M. P. Mattson. 1996. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med. 2: 788-794.
12. Cambi, F., B. Fung, and D. Chikaraishi. 1989. 5′ flanking DNA sequences direct cell-specific expression of rat tyrosine hydroxylase. J. Neurochem. 53: 1656-1659.
13. Carswell, E. A., L. J. Old, R. L. Kassel, S. Green, N. Fiore, and B. Williamson. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72: 3666-3670.
14. Chao, C. C. and S. Hu. 1994. Tumor necrosis factor-alpha potentiates glutamate neurotoxicity in human fetal brain cell cultures. Dev. Neurosci. 16: 172-179.
15. Cheng, B., S. Christakos, and M. P. Mattson. 1994. Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron 12: 139-153.
16. Cho, L., M. Tsunoda, and R. P. Sharma. 1999. Effects of endotoxin and tumor necrosis factor alpha on regional brain neurotransmitters in mice. Nat. Toxins. 7: 187-195.
17. Chu, Z. L., T. A. McKinsey, L. Liu, J. J. Gentry, M. H. Malim, and D. W. Ballard. 1997. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc. Natl. Acad. Sci. USA 94: 10057-10062.
18. Damier, P., E. C. Hirsch, Y. Agid, and A. M. Graybiel. 1999. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 122: 1421-1436.
19. Declercq, W., G. Denecker, W. Fiers, and P. Vandenabeele. 1998. Cooperation of both TNF receptors in inducing apoptosis: Involvement of the TNF receptor-associated factor binding domain of the TNF receptor 75. J. Immunol. 161: 390-399.
20. Eck, M. J., and S. R. Sprang. 1989. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J. Biol. Chem. 264: 17595-17605.
21. Elliott, J. L. 2001. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res. Mol. Brain Res. 95: 172-178.
22. Erickson, S. L., F. J. de Sauvage, K. Kikly, K. Carver-Moore, S. Pitts-Meek, N. Gillett, K. C. Sheehan, R. D. Schreiber, D. V. Goeddel, and M. W. Moore. 1994. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372: 560-563.
23. Forno, L. S., L. E. DeLanney, I. Irwin, D. Di Monte, and J. W. Langston. 1992. Astrocytes and Parkinson's disease. Prog. Brain Res. 94: 429-436.
24. Gamache, P., E. Ryan, C. Svendsen, K. Murayama, and I. N. Acworth. 1993. Simultaneous measurement of monoamines, metabolites and amino acids in brain tissue and microdialysis perfusates. J. Chromatogr. 614: 213-220.
25. Grell, M., F. M. Becke, H. Wajant, D. N. Mannel, and P. Scheurich. 1998. TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur. J. Immunol. 28: 257-263.
26. Guo, G., J. Morrissey, R. McCracken, T. Tolley, H. Liapis, and S. Klahr. 2001. Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis. Am. J. Physiol. Renal Physiol. 280: F777-F785.
27. Hale, K. K., C. G. Smith, S. L. Baker, R. W. Vanderslice, C. H. Squires, T. M. Gleason, K. K. Tucker, T. Kohno, and D. A. Russell. 1995. Multifunctional regulation of the biological effects of TNF-alpha by the soluble type I and type II TNF receptors. Cytokine. 7: 26-38.
28. Hama, T., Y. Kushima, M. Miyamoto, M. Kubota, N. Takei, and H. Hatanaka. 1991. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neuroscience 40: 445-452.
29. Hamre, K., R. Tharp, K. Poon, X. Xiong, and R. J. Smeyne. 1999. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: Quantitative analysis in seven strains of Mus musculus. Brain Res. 828: 91-103.
30. Hirsch, E. C., S. Hunot, P. Damier, B. Brugg, B. A. Faucheux, P. P. Michel, M. Ruberg, M. P. Muriel, A. Mouatt-Prigent, and Y. Agid. 1999. Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease. Adv. Neurol. 80: 9-18.
31. Hofman, F. M., D. R. Hinton, K. Johnson, and J. E. Merrill. 1989. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170: 607-612.
32. Hoskins, J. A., and L. J. Davis. 1989. The acute effect on levels of catecholamines and metabolites in brain, of a single dose of MPTP in 8 strains of mice. Neuropharmacology 28: 1389-1397.
33. Hunot, S., B. Brugg, D. Ricard, P. P. Michel, M. P. Muriel, M. Ruberg, B. A. Faucheux, Y. Agid, and E. C. Hirsch. 1997. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc. Natl. Acad. Sci. USA 94: 7531-7536.
34. Hunot, S., N. Dugas, B. Faucheux, A. Hartmann, M. Tardieu, P. Debre, Y. Agid, B. Dugas, and E. C. Hirsch. 1999. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 19: 3440-3447.
35. Jarskog, L. F., H. Xiao, M. B. Wilkie, J. M. Lauder, and J. H. Gilmore. 1997. Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. Int. J. Dev. Neurosci. 15: 711-716.
36. Kalb, A., H. Bluethmann, M. W. Moore, and W. Lesslauer. 1996. Tumor necrosis factor receptors (Tnfr) in mouse fibroblasts deficient in Tnfr1 or Tnfr2 are signaling competent and activate the mitogen-activated protein kinase pathway with differential kinetics. J. Biol. Chem. 271: 28097-28104.
37. Krajesi, P., and W. S. Wold. 1998. Inhibition of tumor necrosis factor and interferon triggered responses by DNA viruses. Semin. Cell Dev. Biol. 9: 351-358.
38. Kurkowska-Jastrzebska, I., A. Wronska, M. Kohutnicka, A. Czlonkowski, and A. Czlonkowska. 1999. MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease. Acta Neurobiol. Exp. (Warsz) 59: 1-8.
39. Kurkowska-Jastrzebska, I., A. Wronska, M. Kohutnicka, A. Czlonkowski, and A. Czlonkowska. 1999. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 156: 50-61.
40. Liu, J., M. W. Marino, G. Wong, D. Grail, A. Dunn, J. Bettadapura, A. J. Slavin, L. Old, and C. C. Bernard. 1998. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med. 4: 78-83.
41. Liu, S. J., and J. McHowat. 1998. Stimulation of different phospholipase A2 isoforms by TNF-alpha and IL-1beta in adult rat ventricular myocytes. Am. J. Physiol. 275: H1462-H1472.
42. Lucas, R., I. Garcia, Y. R. Donati, M. Hribar, S. J. Mandriota, C. Giroud, W. A. Buurman, L. Fransen, P. M. Suter, G. Nunez, M. S. Pepper, and G. E. Grau. 1998. Both TNF receptors are required for direct TNF-mediated cytotoxicity in microvascular endothelial cells. Eur. J. Immunol. 28: 3577-3586.
43. Mackay, F., J. Rothe, H. Bluethmann, H. Loetscher, and W. Lesslauer. 1994. Differential responses of fibroblasts from wild-type and TNF-R55-deficient mice to mouse and human TNF-alpha activation. J. Immunol. 153: 5274-5284.
44. Mattson, M. P., S. W. Barger, K. Furukawa, A. J. Bruce, T. Wyss-Coray, R. J. Mark, and L. Mucke. 1997. Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res. Brain Res. Rev. 23: 47-61.
45. Mattson, M. P., B. Cheng, S. A. Baldwin, V. L. Smith-Swintosky, J. Keller, J. W. Geddes, S. W. Scheff, and S. Christakos. 1995. Brain injury and tumor necrosis factors induce calbindin D-28k in astrocytes: Evidence for a cytoprotective response. J. Neurosci. Res. 42: 357-370.
46. Mattson, M. P., Y. Goodman, H. Luo, W. Fu, and K. Furukawa. 1997. Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: Evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. J. Neurosci. Res. 49: 681-697.
47. McGeer, P. L., T. Kawamata, D. G. Walker, H. Akiyama, I. Tooyama, and E. G. McGeer. 1993. Microglia in degenerative neurological disease. Glia 7: 84-92.
48. McGeer, P. L., and E. G. McGeer. 1995. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 21: 195-218.
49. McGuire, S. O., Z. D. Ling, J. W. Lipton, C. E. Sortwell, T. J. Collier, and P. M. Carvey. 2001. Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp. Neurol. 169: 219-230.
50. Merrill, J. E., and E. N. Benveniste. 1996. Cytokines in inflammatory brain lesions: Helpful and harmful. Trends Neurosci. 19: 331-338.
51. Mogi, M., M. Harada, T. Kondo, H. Narabayashi, P. Riederer, and T. Nagatsu. 1995. Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci. Lett. 193: 129-132.
52. Mogi, M., M. Harada, T. Kondo, P. Riederer, H. Inagaki, M. Minami, and T. Nagatsu. 1994. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180: 147-150.
53. Mogi, M., M. Harada, T. Kondo, P. Riederer, and T. Nagatsu. 1995. Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect. 9: 87-92.
54. Mogi, M., M. Harada, H. Narabayashi, H. Inagaki, M. Minami, and T. Nagatsu. 1996. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 211: 13-16.
55. Mogi, M., M. Harada, P. Riederer, H. Narabayashi, K. Fujita, and T. Nagatsu. 1994. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165: 208-210.
56. Mogi, M., A. Togari, M. Ogawa, K. Ikeguchi, N. Shizuma, D. Fan, I. Nakano, and T. Nagatsu. 1998. Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1beta and nerve growth factor in the striatum. Neurosci. Lett. 250: 25-28.
57. Mogi, M., A. Togari, K. Tanaka, N. Ogawa, H. Ichinose, and T. Nagatsu. 1999. Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction. Neurosci. Lett. 268: 101-104.
58. Nawashiro, H., K. Tasaki, C. A. Ruetzler, and J. M. Hallenbeck. 1997. TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 17: 483-490.
59. Nuovo, G. J., and M. L. Alfieri. 1996. AIDS dementia is associated with massive, activated HIV-1 infection and concomitant expression of several cytokines. Mol. Med. 2: 358-366.
60. Old, L. J. 1988. Tumor necrosis factor. Sci. Am. 258: 59-75.
61. Rothe, J., W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Steinmetz, and H. Bluethmann. 1993. Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364: 798-802.
62. Rothwell, N. J., and P. J. Strijbos. 1995. Cytokines in neurodegeneration and repair. Int. J. Dev. Neurosci. 13: 179-185.
63. Rozas, G., and G. J. Labandeira. 1997. Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test. Brain Res. 749: 188-199.
64. Scherbel, U., R. Raghupathi, M. Nakamura, K. E. Saatman, J. Q. Trojanowski, E. Neugebauer, M. W. Marino, and T. K. McIntosh. 1999. Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc. Natl. Acad. Sci. USA 96: 8721-8726.
65. Selmaj, K., C. S. Raine, B. Cannella, and C. F. Brosnan. 1991. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 87: 949-954.
66. Shinpo, K., S. Kikuchi, F. Moriwaka, and K. Tashiro. 1999. Protective effects of the TNF-ceramide pathway against glutamate neurotoxicity on cultured mesencephalic neurons. Brain Res. 819: 170-173.
67. Shohami, E., R. Bass, D. Wallach, A. Yamin, and R. Gallily. 1996. Inhibition of tumor necrosis factor alpha (TNFalpha) activity in rat brain is associated with cerebroprotection after closed head injury. J. Cereb. Blood Flow Metab. 16: 378-384.
68. Shohami, E., R. Gallily, R. Mechoulam, R. Bass, and T. Ben-Hur. 1997. Cytokine production in the brain following closed head injury: Dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J. Neuroimmunol. 72: 169-177.
69. Sriram, K., J. M. Matheson, D. B. Miller, M. I. Luster, and J. P. O'callaghan. 2001. Mice deficient in TNF-3 receptors are protected against MPTP-induced dopaminergic neurotoxicity. Soc. Neurosci. Abstr. 194.12.
70. Sugarman, B. J., B. B. Aggarwal, P. E. Hass, I. S. Figari, M. A. J. Palladino, and H. M. Shepard. 1985. Recombinant human tumor necrosis factor-alpha: Effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945.
71. Sullivan, P. G., A. J. Bruce-Keller, A. G. Rabchevsky, S. Christakos, D. K. Clair, M. P. Mattson, and S. W. Scheff. 1999. Exacerbation of damage and altered NF-kappaB activation in mice lacking tumor necrosis factor receptors after traumatic brain injury. J. Neurosci. 19: 6248-6256.
72. Talley, A. K., S. Dewhurst, S. W. Perry, S. C. Dollard, S. Gummuluru, S. M. Fine, D. New, L. G. Epstein, H. E. Gendelman, and H. A. Gelbard. 1995. Tumor necrosis factor alpha-induced apoptosis in human neuronal cells: Protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA. Mol. Cell Biol. 15: 2359-2366.
73. Tamatani, M., Y. H. Che, H. Matsuzaki, S. Ogawa, H. Okado, S. Miyake, T. Mizuno, and M. Tohyama. 1999. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J. Biol. Chem. 274: 8531-8538.
74. Tartaglia, L. A., D. V. Goeddel, C. Reynolds, I. S. Figari, R. F. Weber, B. M. Fendly, and M. A. J. Palladino. 1993. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J. Immunol. 151: 4637-4641.
75. Tchelingerian, J. L., M. Monge, F. Le Saux, B. Zalc, and C. Jacque. 1995. Differential oligodendroglial expression of the tumor necrosis factor receptors in vivo and in vitro. J. Neurochem. 65: 2377-2380.
76. Tomimoto, H., I. Akiguchi, H. Wakita, A. Kinoshita, A. Ikemoto, S. Nakamura, and J. Kimura. 1996. Glial expression of cytokines in the brains of cerebrovascular disease patients. Acta Neuropathol. (Berlin) 92: 281-287.
77. von Coelln, R., K. Unsicker, and K. Krieglstein. 1995. Screening of interleukins for survival-promoting effects on cultured mesencephalic dopaminergic neurons from embryonic rat brain. Brain Res. Dev. Brain Res. 89: 150-154.
78. Westwick, J. K., C. Weitzel, A. Minden, M. Karin, and D. A. Brenner. 1994. Tumor necrosis factor alpha stimulates AP-1 activity through prolonged activation of the c-Jun kinase. J. Biol. Chem. 269: 26396-26401.
79. Wilde, G. J., A. K. Pringle, L. E. Sundstrom, D. A. Mann, and F. Iannotti. 2000. Attenuation and augmentation of ischaemia-related neuronal death by tumour necrosis factor-alpha in vitro. Eur. J. Neurosci. 12: 3863-3870.
80. Wilt, S. G., E. Milward, J. M. Zhou, K. Nagasato, H. Patton, R. Rusten, D. E. Griffin, M. O'Connor, and M. Dubois-Dalcq. 1995. In vitro evidence for a dual role of tumor necrosis factor-alpha in human immunodeficiency virus type 1 encephalopathy. Ann. Neurol. 37: 381-394.
81. Wong, G. H., and D. V. Goeddel. 1988. Induction of manganous superoxide dismutase by tumor necrosis factor: Possible protective mechanism. Science 242: 941-944.
82. Yamada, Y., and N. Fausto. 1998. Deficient liver regeneration after carbon tetrachloride injury in mice lacking type 1 but not type 2 tumor necrosis factor receptor. Am. J. Pathol. 152: 1577-1589.